Get started
Kura Oncology, Inc.Kura Oncology, Inc.Kura Oncology, Inc.

Kura Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

KURA chart


Full chart

KURA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪499.21 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.02 USD
Net income (FY)
‪−173.98 M‬ USD
Revenue (FY)
‪53.88 M‬ USD
Shares float
‪75.38 M‬
Beta (1Y)
1.43

Employees


Employees (FY)
192
Change (1Y)
+50 +35.21%
Revenue / Employee (1Y)
‪280.64 K‬ USD
Net income / Employee (1Y)
‪−906.16 K‬ USD

About Kura Oncology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Troy E. Wilson
Website
kuraoncology.com
Headquarters
San Diego
Founded
2014
FIGI
BBG008974342
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

KURA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where KURA is featured.

See all sparks 


Check out other big names from the same industry as KURA.

Frequently Asked Questions


The current price of KURA is 6.18 USD — it has increased by 4.75% in the past 24 hours. Watch Kura Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kura Oncology, Inc. stocks are traded under the ticker KURA.
KURA stock has risen by 4.92% compared to the previous week, the month change is a −21.27% fall, over the last year Kura Oncology, Inc. has showed a −64.91% decrease.
We've gathered analysts' opinions on Kura Oncology, Inc. future price: according to them, KURA price has a max estimate of 40.00 USD and a min estimate of 10.00 USD. Watch KURA chart and read a more detailed Kura Oncology, Inc. stock forecast: see what analysts think of Kura Oncology, Inc. and suggest that you do with its stocks.
KURA reached its all-time high on Dec 9, 2020 with the price of 43.00 USD, and its all-time low was 2.50 USD and was reached on Jul 5, 2016. View more price dynamics on KURA chart.
See other stocks reaching their highest and lowest prices.
KURA stock is 9.07% volatile and has beta coefficient of 1.43. Track Kura Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kura Oncology, Inc. there?
Today Kura Oncology, Inc. has the market capitalization of ‪499.21 M‬, it has increased by 1.01% over the last week.
Yes, you can track Kura Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Kura Oncology, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
KURA earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.64 USD resulting in a 65.39% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about Kura Oncology, Inc. earnings.
Kura Oncology, Inc. revenue for the last quarter amounts to ‪53.88 M‬ USD, despite the estimated figure of ‪53.82 M‬ USD. In the next quarter, revenue is expected to reach ‪17.53 M‬ USD.
KURA net income for the last quarter is ‪−19.22 M‬ USD, while the quarter before that showed ‪−54.40 M‬ USD of net income which accounts for 64.68% change. Track more Kura Oncology, Inc. financial stats to get the full picture.
No, KURA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 192 employees. See our rating of the largest employees — is Kura Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kura Oncology, Inc. EBITDA is ‪−192.35 M‬ USD, and current EBITDA margin is −356.97%. See more stats in Kura Oncology, Inc. financial statements.
Like other stocks, KURA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kura Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kura Oncology, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kura Oncology, Inc. stock shows the strong sell signal. See more of Kura Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.